|
|
Chronically Ill Patients Want an Answer, Not a Label
Identifying the cause of chronic illness is the first step toward achieving a favorable outcome. Integrative clinicians rely on the Organix™ Profile to reveal the nutritional and metabolic basis of patient symptoms, just as traditional practitioners might use a serum chemistry to establish a diagnostic baseline. The Organix Profile provides a view into the body's cellular metabolic processes and the efficiency of metabolic function. Identifying metabolic blocks that can be treated nutritionally allows individual tailoring of interventions that maximize patient responses and lead to improved patient outcomes.
Organic acids are metabolic intermediates produced in pathways of central energy production, detoxification, neurotransmitter breakdown, or intestinal microbial activity. Accumulation of specific organic acids in urine often signals a metabolic inhibition or block. This may be due to a nutrient deficiency, an inherited enzyme deficit, toxic build-up, or drug effect.
Organix Profiles Include:
- Organix Comprehensive* - The complete organic acids profile
- Organix Basic - Great for follow up testing when dysbiosis markers aren't needed
- Organix Dysbiosis* - Measures the by-products of microbial metabolism to access overgrowth and guide and monitor therapy
*Some analytes may not be reported in New York profiles. Please see Clinician Info and CPT Codes for details
|
|
|

From a single urine specimen, the Organix Profile provides important information in the areas of:
- Vitamin and mineral insufficiencies
- Amino acid insufficiencies like carnitine and NAC
- Oxidative damage and anti-oxidant sufficiency markers
- Indicators to assess detoxification sufficiency
- The best functional markers of B-complex deficiency
- Neurotransmitter metabolites to assess CNS function
- Mitochondrial energy production assessment via citric acid cycle components
- Methylation sufficiency status
- Lipoic acid and CoQ10 sufficiency markers
- Specific dysbiosis markers for bacterial and yeast overgrowth
|
|
Clinician Info
| Test name: |
0291 - Organix™ Basic Profile 0088 - Neopterin/Biopterin Profile*
|
|
|
| Description: |
The Organix™ Basic Profile provides a view into the body's
cellular metabolic processes and the efficiency of metabolic function. Identifying metabolic blocks that can be treated nutritionally allows individual tailoring of interventions that maximize patient responses and lead to improved patient outcomes.
Organic acids are metabolic intermediates that are produced in
pathways of central energy production, detoxification, neuro-
transmitter breakdown, or intestinal microbial activity. Marked
accumulation of specific organic acids detected in urine often signals a metabolic inhibition or block. The metabolic block may be due to a nutrient deficiency, an inherited enzyme deficit, toxic build-up, or drug effect.
|
|
|
| Method: |
LC/MS-MS, Spectrophotometry |
|
|
| Turnaround time: |
8-14 days, 12 days average |
|
|
|
Analytes:
|
B-VITAMIN INSUFFICIENCY
Pyruvate Alpha-Ketoglutarate Alpha-Ketoisovalerate Alpha-Ketoisocaproate Alpha-Keto-Beta-Methylvalerate Xanthurenate Beta-Hydroxyisovalerate Methylmalonate Formiminoglutamate
CELLULAR ENERGY
Adipate Suberate Ethylmalonate Lactate Beta-Hydroxybutyrate Succinate Fumarate Malate Hydroxymethylglutarate
NEURAL FUNCTION
Vanilmandelate Homovanillate 5-Hydroxyindoleacetate Kynurenate Quinolinate
DETOXIFICATION
Citrate cis-Aconitate Isocitrate 2-Methylhippurate Orotate Glucarate Alpha-Hydroxybutyrate Pyroglutamate Creatinine
*Not reported in New York profiles
|
|
CPT codes:
| 83497 |
- |
| 5-Hydroxyindoleacetate |
| 82507 |
- |
| Citrate |
| 82570 |
- |
| Creatinine |
| 83605 x1 |
- |
| D-Lactate |
| 83150 |
- |
| Homovanillate |
| 84210 |
- |
| Pyruvate |
| 84585 |
- |
| Vanilmandelate |
| 83921 x26 |
- |
| Organic acid, single, quantitative |
|
The PDF should now automatically load in another browser window.
If the PDF has not yet loaded, please click link below:
|
| |
|
|
Mitochondrial Dysfunction and Disease.
Neustadt J, Integrative Medicine. 2006 June/July 5(3): p.14-20.
How to Assess Patient Biochemical and Nutritional Individuality through Organic Acid Testing.
Burdette, Cheryl K., Townsend Letter for Doctors and Patients. 2006.
Urinary Markers of Intestinal Yeast.
Lord RS, Townsend Letter for Doctors. 2003. December (245): p. 96-97
Urinary Markers of Yeast Overgrowth.
Lord RS, Burdette C, and Bralley JA, Integrative Medicine. 2004. 3(5): p. 24-29.
Autistic therapies focused by laboratory data. Part I: Organic Acids.
Lord RS, Nutrition Practitioner. 2005. 6(3): p. 1-7.
Occupational and lifestyle factors and urinary 8-hydroxydeoxyguanosine.
Irie M., Tamae K., Iwamoto-Tanaka N., Kasai, H. Cancer Sci, 2005 Sep; 96(9):600-6.
Urine methylmalonic acid measurements for the assessment of cobalamin deficiency related to neuropsychiatric disorders.
Gültepe M, Ozcan O, Avşar K, Cetin M, Ozdemir AS, Gök M. Clin Biochem. 2003 Jun;36(4):275-82.
3-Hydroxypropionic Acid and Methylcitric Acid Are Not Reliable Indicators of Marginal Biotin Deficiency in Humans
Donald M Mock, Cindy L Henrich-Shell, Nadine Carnell, Phyllis Stumbo, Nell I Mock. The Journal of Nutrition. Bethesda:
Feb 2004. Vol. 134, Iss. 2; pg. 317, 4 pgs
Effects of arginine treatment on nutrition, growth and urea cycle function in seven Japanese boys
with late-onset ornithine transcarbamylase deficiency.
Nagasaka H, Yorifuji T, Murayama K, Kubota M, Kurokawa K, Murakami T, Kanazawa
M, Takatani T, Ogawa A, Ogawa E, Yamamoto S, Adachi M, Kobayashi K, Takayanagi M.
Eur J Pediatr. 2006 Sep;165(9):618-24. Epub 2006 May 16.
Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies.
Rider LG, Schiffenbauer AS, Zito M, Lim KL, Ahmed A, Zemel LS, Rennebohm RM, Passo MH, Summers RM, Hicks JE,
Lachenbruch PA, Heyes MP, Miller FW; Clin Chem. 2002. Oct;48(10):1681-8.
Catecholamine metabolism: a contemporary view with implications for physiology and medicine.
Eisenhofer G, Kopin IJ, Goldstein DS. Pharmacol Rev. 2004 Sep;56(3):331-49.
|
|